HIMS 8-K: Smart Summary

Hims & Hers Health, Inc. reported Q1 2026 financial results on May 11, 2026, with revenue of $608.1M, up 4% year-over-year, while net loss was $92.1M compared to net income of $49.5M in Q1 2025. The Company raised its full year 2026 revenue guidance to $2.8B to $3B and updated Adjusted EBITDA guidance to $275M to $350M. The Company also announced a strategic pivot expanding its assortment of branded GLP-1 products and plans a proposed acquisition of Eucalyptus expected to close mid-2026.

• Revenue: $608.1M in Q1 2026 vs. $586M in Q1 2025, up 4% YoY
• Gross profit: $396.8M in Q1 2026 vs. $430.7M in Q1 2025; gross margin 65% vs. 73% YoY
• Adjusted gross margin: 70% in Q1 2026 vs. 73% in Q1 2025
• (Loss) income from operations: ($78.3M) in Q1 2026 vs. $57.9M in Q1 2025
• Net (loss) income: ($92.1M) in Q1 2026 vs. net income of $49.5M in Q1 2025
• Basic EPS: $(0.40) in Q1 2026 vs. $0.22 in Q1 2025; Diluted EPS: $(0.40) vs. $0.20 in Q1 2025
• Adjusted EBITDA: $44.3M (7% margin) in Q1 2026 vs. $91.1M (16% margin) in Q1 2025
• Net cash provided by operating activities: $89.4M in Q1 2026 vs. $109.1M in Q1 2025
• Free Cash Flow: $53M in Q1 2026 vs. $50.1M in Q1 2025

• United States Revenue: $529.9M in Q1 2026 vs. $578.7M in Q1 2025, down 8% YoY
• Rest of the World Revenue: $78.2M in Q1 2026 vs. $7.3M in Q1 2025, up 969% YoY
• Total Revenue: $608.1M in Q1 2026 vs. $586M in Q1 2025, up 4% YoY
• Subscribers (end of period): 2,584 thousand in Q1 2026 vs. 2,366 thousand in Q1 2025, up 9% YoY
• Monthly Revenue per Average Subscriber: $80 in Q1 2026 vs. $85 in Q1 2025, down 6% YoY

• Cash and cash equivalents: $222.3M as of March 31, 2026 vs. $228.6M as of December 31, 2025
• Short-term available-for-sale investments: $528.6M as of March 31, 2026 vs. $348.9M as of December 31, 2025
• Long-term available-for-sale investments: $0 as of March 31, 2026 vs. $351.3M as of December 31, 2025
• Convertible senior notes, net: $974.1M as of March 31, 2026 vs. $972.6M as of December 31, 2025
• Payments for taxes related to net share settlement of equity awards: $39.2M in Q1 2026 vs. $25.7M in Q1 2025
• Payments for acquisition-related earn-out consideration: $43.7M in Q1 2026
• Proceeds from exercise of vested stock options: $5M in Q1 2026 vs. $3.9M in Q1 2025
• No dividends or share repurchases disclosed

• "2026 is a defining year for Hims & Hers. We're not just growing, we're pulling away from the field on our path to becoming the world's largest consumer health platform," said Andrew Dudum, co-founder and CEO.
• "We expect growth to accelerate from here, and have high conviction in our 2030 targets of at least $6.5B in revenue and $1.3B in Adjusted EBITDA," said Yemi Okupe, Chief Financial Officer.

• Q2 2026 revenue guidance: $680M to $700M
• Q2 2026 Adjusted EBITDA guidance: $35M to $55M, reflecting an Adjusted EBITDA margin of 5% to 8%
• Full year 2026 revenue guidance raised to $2.8B to $3B
• Full year 2026 Adjusted EBITDA guidance updated to $275M to $350M, reflecting an Adjusted EBITDA margin of 10% to 12%
• Guidance excludes any potential contributions from the proposed acquisition of Eucalyptus, expected to close during the middle of calendar year 2026
• Long-term 2030 targets: at least $6.5B in revenue and $1.3B in Adjusted EBITDA